Evidence map›Paper›PMID 37917600›Full record

ArticlePLoS pathogens2023

Proline catabolism is a key factor facilitating Candida albicans pathogenicity.

Fitz Gerald S Silao, Tong Jiang, Biborka Bereczky-Veress, Andreas Kühbacher, Kicki Ryman, Nathalie Uwamohoro, Sabrina Jenull, Filomena Nogueira, Meliza Ward, Thomas Lion and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Genomic Insights intoJournal of fungi (Basel, Switzerland) · 2025
    Article
  4. Microorganisms · 2025
    Review
  5. Article
  6. The utility ofFrontiers in immunology · 2024
    Review
  7. Frontiers in immunology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 4 countries.

Fitz Gerald S SilaoDepartment of Molecular Biosciences, The Wenner-Gren Institute, Science for Life Laboratory, Stockholm University, Solna, Sweden.
Tong JiangShanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China.
Biborka Bereczky-VeressIntravital Microscopy Facility, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.
Andreas KühbacherDepartment of Molecular Biotechnology, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart, Germany.
Kicki RymanDepartment of Molecular Biosciences, The Wenner-Gren Institute, Science for Life Laboratory, Stockholm University, Solna, Sweden.
Nathalie UwamohoroClinical Microbiology and Umeå Centre for Microbial Research (UCMR), Umeå University Umeå, Sweden.
Sabrina JenullMedical University of Vienna, Max F. Perutz Laboratories GmbH, Department of Medical Biochemistry, Vienna, Austria.
Filomena NogueiraMedical University of Vienna, Max F. Perutz Laboratories GmbH, Department of Medical Biochemistry, Vienna, Austria.
Meliza WardDepartment of Molecular Biosciences, The Wenner-Gren Institute, Science for Life Laboratory, Stockholm University, Solna, Sweden.
Thomas LionSt. Anna Kinderkrebsforschung e.V., Children's Cancer Research Institute, Vienna, Austria.
Constantin F UrbanClinical Microbiology and Umeå Centre for Microbial Research (UCMR), Umeå University Umeå, Sweden.
Steffen RuppDepartment of Molecular Biotechnology, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart, Germany.
Karl KuchlerMedical University of Vienna, Max F. Perutz Laboratories GmbH, Department of Medical Biochemistry, Vienna, Austria.
Changbin ChenShanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China.
Christiane PeuckertIntravital Microscopy Facility, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.
Per O LjungdahlDepartment of Molecular Biosciences, The Wenner-Gren Institute, Science for Life Laboratory, Stockholm University, Solna, Sweden.ORCID 0000-0002-6625-3540
Stockholm University · SEChinese Academy of Sciences · CNFraunhofer Institute for Interfacial Engineering and Biotechnology · DEMax Perutz Labs · ATUmeå University · SESt Anna Children's Hospital · ATUniversity of Veterinary Medicine Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Candida albicans, the primary etiology of human mycoses, is well-adapted to catabolize proline to obtain energy to initiate morphological switching (yeast to hyphal) and for growth. We report that put1-/- and put2-/- strains, carrying defective Proline UTilization genes, display remarkable proline sensitivity with put2-/- mutants being hypersensitive due to the accumulation of the toxic intermediate pyrroline-5-carboxylate (P5C), which inhibits mitochondrial respiration. The put1-/- and put2-/- mutations attenuate virulence in Drosophila and murine candidemia models and decrease survival in human neutrophils and whole blood. Using intravital 2-photon microscopy and label-free non-linear imaging, we visualized the initial stages of C. albicans cells infecting a kidney in real-time, directly deep in the tissue of a living mouse, and observed morphological switching of wildtype but not of put2-/- cells. Multiple members of the Candida species complex, including C. auris, are capable of using proline as a sole energy source. Our results indicate that a tailored proline metabolic network tuned to the mammalian host environment is a key feature of opportunistic fungal pathogens.

Indexed as

Candida albicansSaccharomyces cerevisiaeAnimalsCandidaHumansMammalsMiceProlineVirulenceProline

Identifiers

PMID37917600
PMCPMC10621835
OpenAlexW4388215416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.